Extracorporeal Shockwave Therapy for the Treatment of Refractory Chronic Angina Pectoris
Unknown statusPhase 1NCT01567644
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with refractory angina not amenable to revascularization with angioplasty or bypass surgery.
Study details
- Official title
- Clinical Trial Evaluating the Treatment of Patients With Refractory Chronic Angina Pectoris With Low Intensity Extracorporeal Shockwave Therapy Device
- Conditions
- Refractory Angina Pectoris
- Interventions
- Device: Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
- Sponsor
- Medispec
- Collaborators
- Heart and Diabetes Center North-Rhine Westfalia
- Start date
- 2008-01
- Primary completion
- 2012-04
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Diagnosed with chronic stable angina pectoris. * Documented myocardial segments with reversible ischemia * AP CCS class of III-IV. * Stable dosage of medication used to treat angina for at least 6 weeks prior to enrollment. * Exercise tolerance time \< 10 min (modified Bruce) * Two ETT tests results (within two weeks) averaging no more than 25% of their mean * Documented epicardial coronary artery disease not amenable to angioplasty or CABG. * Signed an IRB approved informed consent form. * Life expectancy of \> 12 months. Exclusion Criteria: * Intraventricular thrombus * Malignancy in the area of treatment * Severe COPD * No smoking during the study procedure * MI less \< 3 months prior to treatment * Severe Valvular disease * Child bearing potential
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT01567644